GSK's Q1 2025 earnings will reveal progress in specialty medicines amid regulatory headwinds. Learn what to watch when the ...

GSK PLC closed 22.73% below its 52-week high of £18.24, which the company reached on May 16th.

NET PROFIT FORECAST: Net profit is expected to rise to 1.67 billion pounds from 1.05 billion pounds, according to a consensus provided by the company. London-listed shares in GSK are up 4.1% since the ...

Compared with a control group who had prescriptions for other inhaled steroids (including the authorized generic of ...

We recently published a list of the 11 Best Undervalued UK Stocks to Buy Right Now. In this article, we are going to take a ...

The stock market saw 75 stocks at 52-week highs and 25 at lows on Thursday, with Nifty 50 and Sensex declining due to ...

Home First Finance Company India Ltd recorded volume of 4.22 lakh shares by 10:47 IST on BSE, a 25.89 times surge over two-week average daily volume of 16300 shares ...

U.K. regulators cleared a multiple myeloma drug GSK withdrew from market three years ago. Elsewhere, RNA editing startup Airna tapped a former Sarepta executive to oversee its pipeline.

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday authorized GSK plc’s (NYSE:GSK) Blenrep.

The London-based pharmaceutical company said Blenrep, or belantamab mafodotin, was approved for the treatment of adult patients with multiple myeloma in combination with bortezomib plus dexamethasone, ...

Arexvy, already approved in over 60 countries, was supported by trial data showing safety and immune response in the 50–59 age group. GSK said more than 13 million adults in the US fall into this ...

In spring 2021, my family sold a big lump of GSK shares. Four years later, we have no regrets. Indeed, with the GSK share price stumbling, we may buy soon. When investing, your capital is at risk.